^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR mutation + TP53 mutation + NF1 mutation

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor, TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1, NFNS, NF1, Neurofibromin 1, Neurofibromatosis-Related Protein NF-1, Truncated Neurofibromin 1
    Entrez ID:
    1956; 7157; 4763
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer (IASLC-TTLC 2023)
    The inferior outcomes in patients with EGFR-mutant NSCLC with tumors harboring a co-occurring TP53 mutation may be due to additional TSG alterations rather than TP53 mutational status alone. This may have implications for understanding the biologic underpinnings of differential outcomes to EGFR-TKIs.
    Clinical • BRCA Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1)
    |
    TP53 mutation • EGFR mutation • TP53 wild-type • EGFR mutation + TP53 mutation + ARID1A mutation • EGFR mutation + TP53 mutation + BRCA1 mutation • EGFR mutation + TP53 mutation + NF1 mutation • EGFR mutation + TP53 mutation + PTEN mutation • EGFR mutation + TP53 mutation + RB1 mutation